Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Gori S, et al. Among authors: spazzapan s. Ann Oncol. 2012 Jun;23(6):1436-41. doi: 10.1093/annonc/mdr474. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039084 Free article.
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D. Muraro E, et al. Among authors: spazzapan s. J Transl Med. 2015 Jun 27;13:204. doi: 10.1186/s12967-015-0567-0. J Transl Med. 2015. PMID: 26116238 Free PMC article. Clinical Trial.
Treatment of older breast cancer patients with high recurrence risk.
Crivellari D, Spazzapan S, Lombardi D, Berretta M, Magri MD, Sorio R, Scalone S, Veronesi A. Crivellari D, et al. Among authors: spazzapan s. Crit Rev Oncol Hematol. 2003 Jun;46(3):241-6. doi: 10.1016/s1040-8428(03)00023-4. Crit Rev Oncol Hematol. 2003. PMID: 12791423 Review.
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M. Cortes J, et al. Among authors: spazzapan s. Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051. Ann Oncol. 2018. PMID: 29481630 Free article. Clinical Trial.
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O. Regan MM, et al. Among authors: spazzapan s. Ann Oncol. 2017 Sep 1;28(9):2225-2232. doi: 10.1093/annonc/mdx285. Ann Oncol. 2017. PMID: 28911092 Free PMC article. Clinical Trial.
Ifosfamide in advanced/disseminated breast cancer.
Sorio R, Lombardi D, Spazzapan S, La Mura N, Tabaro G, Veronesi A. Sorio R, et al. Among authors: spazzapan s. Oncology. 2003;65 Suppl 2:55-8. doi: 10.1159/000073360. Oncology. 2003. PMID: 14586149 Review.
67 results